Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients
Archives of Dermatological Research · 2024
DOI: 10.1007/s00403-024-02876-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Dermatological Research, 2024. Verfasst von Maxwell Green und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tulane University School of Medicine, New Orleans, LA, USA. Hauptthemen laut MEDLINE: Hydroxychloroquine, Drug Monitoring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hydroxychloroquine (HCQ) is an immunomodulator used in dermatology and rheumatology. Side effects may be observed on routine monitoring studies before they become clinically apparent. The goal of this retrospective chart review was to assess laboratory abnormalities in dermatologic and rheumatologic patients taking HCQ. Medical records of patients prescribed HCQ were retrospectively reviewed. Demographics, reported side effects, and parameters on baseline and follow-up complete blood count (CBC) and comprehensive metabolic panel (CMP) were recorded and graded. Laboratory abnormalities were considered severe if they were grade 3 or greater according to Common Terminology Criteria for Adverse Events v3.0 and persistent if they continued beyond subsequent laboratory testing. Of 646 eligible charts, 289 had monitoring studies for review. There were 35 severe (grade 3 or 4, 35/289; 12%) adverse events that developed, as noted on CBC or CMP. Of these 35 severe adverse events, 25 self-corrected on subsequent testing, and 10 (10/289, 3%) across 9 patients were persistent, including glomerular filtration rate, alanine transferase, alkaline phosphatase, glucose, hemoglobin and lymphopenia abnormalities. Of these 10 abnormalities, 7/10 (70%) were unlikely due to hydroxychloroquine use according to the calculated Naranjo score for each patient. Severe laboratory abnormalities while taking hydroxychloroquine are rare, even in a population with a high rate of comorbidities. Among the abnormalities observed, the majority of them (70%) were likely due to disease progression or a medication other than hydroxychloroquine. CBC and CMP monitoring for the reason of observing abnormalities while on HCQ should be at the discretion of the prescribing physician.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tulane University School of Medicine, New Orleans, LA, USA.
- Department of Dermatology, Tulane University School of Medicine, New Orleans, LA, USA.
- Department of Dermatology, Tulane University School of Medicine, New Orleans, LA, USA. dkuraiti@tulane.edu.
- Department of Dermatology, Roswell Park Cancer Center, 665 Elm St, Buffalo, NY, 14263, USA. dkuraiti@tulane.edu.
Zitieren
APA
Green, M., Williams, L., Boh, E., & Kuraitis, D. (2024). Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-02876-7
Vancouver
Green M, Williams L, Boh E, Kuraitis D. Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients. Archives of Dermatological Research. 2024. doi:10.1007/s00403-024-02876-7
BibTeX
@article{Green2024,
author = {Green, Maxwell and Williams, Laura and Boh, Erin and Kuraitis, Drew},
title = {Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients},
journal = {Archives of Dermatological Research},
year = {2024},
doi = {10.1007/s00403-024-02876-7}
}
EUVIMED